血液系统恶性肿瘤中的CXCR4靶向PET显像:系统评价与Meta分析
该系统评价与Meta分析(遵循PRISMA-DTA,检索至2024年3月1日)纳入18项研究,评估CXCR4靶向PET在血液系统恶性肿瘤中的检出、显像与预后价值。B细胞淋巴瘤汇总检出率为99.4%(95%CI:88.3%-100%),多发性骨髓瘤患者水平汇总敏感度77.8%(95%CI:64.4%-87.2%),高于18F-FDG PET的65.0%(95%CI:55.2%-73.7%)。作者认为CXCR4 PET是评估血液系统恶性肿瘤的有用显像工具,在特定临床场景中似乎优于当前标准治疗显像。
要点
- B细胞淋巴瘤CXCR4 PET汇总检出率99.4%(95%CI:88.3%-100%)。
- 多发性骨髓瘤患者水平汇总敏感度:CXCR4 PET 77.8% vs 18F-FDG PET 65.0%。
- 中枢神经系统淋巴瘤中CXCR4 PET在患者和病灶水平均为100%准确率,肿瘤/本底比显著高于18F-FDG PET。
核心结论
- CXCR4 PET可作为评估血液系统恶性肿瘤的有用显像工具,尤其对B细胞淋巴瘤和多发性骨髓瘤患者。
- 在特定临床场景中,CXCR4 PET似乎优于当前标准治疗显像。
研究设计与样本
- 本研究遵循PRISMA-DTA,系统检索主要医学文献数据库至2024年3月1日,初检共获得1428项研究。
- 最终18项研究符合系统评价与Meta分析条件;采用随机效应模型合并2×2列联表得出的敏感度,并计算SUV max的汇总均值,分析使用R软件。
主要发现
- 12项研究(320例患者)涉及B细胞淋巴瘤,CXCR4 PET汇总检出率为99.4%(95%CI:88.3%-100%)。
- 5项研究(209例患者)涉及边缘区淋巴瘤,汇总敏感度为97.6%(95%CI:79.7%-99.8%)。
- 中枢神经系统淋巴瘤研究中,CXCR4 PET在患者水平和病灶水平均达100%准确率,且肿瘤/本底比显著高于18F-FDG PET。
- 多发性骨髓瘤5项研究(116例患者)患者水平汇总敏感度:CXCR4 PET 77.8%(95%CI:64.4%-87.2%)vs 18F-FDG PET 65.0%(95%CI:55.2%-73.7%)。
- CXCR4 PET汇总SUV max为13.6(95%CI:9.3-17.8),18F-FDG PET为9.0(95%CI:6.3-11.7);CXCR4 PET衍生参数是多发性骨髓瘤存活的显著预测因素。
关键数值与推荐
- B细胞淋巴瘤:CXCR4 PET汇总检出率99.4%(95%CI:88.3%-100%)。
- 边缘区淋巴瘤:CXCR4 PET汇总敏感度97.6%(95%CI:79.7%-99.8%)。
- 多发性骨髓瘤:CXCR4 PET患者水平汇总敏感度77.8%(95%CI:64.4%-87.2%),18F-FDG PET为65.0%(95%CI:55.2%-73.7%)。
- SUV max:CXCR4 PET 13.6(95%CI:9.3-17.8)vs 18F-FDG PET 9.0(95%CI:6.3-11.7)。
临床怎么用
- 作者认为CXCR4 PET可作为评估血液系统恶性肿瘤的有用显像工具,尤其对B细胞淋巴瘤和多发性骨髓瘤患者;在特定临床场景中似乎优于当前标准治疗显像。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aims of this study were to perform a comprehensive review and meta-analyses and to report pooled diagnostic results on CXCR4-targeted PET, particularly considering detection, visualization, and prognostication. PATIENTS AND METHODS: This study followed PRISMA-DTA. A systematic search was conducted on major medical literature databases up to March 1, 2024. The search strategy was designed to include CXCR4 PET studies in hematologic malignancies. A random-effects model combined sensitivity values derived from 2-by-2 contingency tables. Pooled means for SUV max were computed. Analyses were performed by R software. RESULTS: The initial search resulted in a total of 1428 studies. Ultimately, 18 were eligible for systematic review and meta-analytic calculations. Twelve studies (320 patients) included B-cell lymphoma. The pooled detection rate of CXCR4 PET was 99.4% (95% confidence interval [CI]: 88.3%-100%). Marginal zone lymphoma was investigated in 5 studies (209 patients), with a pooled sensitivity of 97.6% (95% CI: 79.7%-99.8%). In studies on central nervous system lymphoma, CXCR4 PET demonstrated 100% accuracy at both patient and lesion levels. Also, it demonstrated a significantly higher tumor-to-background ratio than 18 F-FDG PET. For multiple myeloma, 5 studies (116 patients) showed a patient-level pooled sensitivity of 77.8% (95% CI: 64.4%-87.2%), whereas 18 F-FDG PET had 65.0% (95% CI: 55.2%-73.7%). The pooled SUV max for CXCR4 PET was 13.6 (95% CI: 9.3-17.8) versus 9.0 (95% CI: 6.3-11.7) for 18 F-FDG PET. Additionally, CXCR4 PET-derived parameters were significant predictors of survival in multiple myeloma. CONCLUSIONS: CXCR4 PET can be a helpful imaging tool for evaluating hematologic malignancies, particularly in B-cell lymphoma and multiple myeloma patients. In specific clinical scenarios, it appears to be superior compared with the current standard-of-care imaging.
引用
- Chavoshi M, Mirshahvalad SA, Kohan A, et al. CXCR4-Targeted PET Imaging in Hematologic Malignancies: A Systematic Review and Meta-analysis. Clin Nucl Med. 2024. PMID: 39259697. doi:10.1097/RLU.0000000000005426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。